KPV vs Larazotide
Two gut peptides at opposite ends of the pipeline: KPV has never been tried in humans, larazotide was tried in celiac disease and its pivotal Phase 3 failed.
KPV
The anti-inflammatory tail of α-MSH, with real mechanism and real mouse data — but essentially no human trials.
Full KPV evidence reviewLarazotide
AT-1001
A tight-junction regulator with real celiac Phase 2 data — but its pivotal Phase 3 failed, and the supplement use runs far ahead of the evidence.
Full Larazotide evidence reviewSide by side
| KPV | Larazotide | |
|---|---|---|
| Marketed for | Inflammation, gut, wound healing | Leaky gut, celiac disease |
| Evidence grade | Preclinical / minimal | Clinical data |
| Family | Immune / metabolic | Immune / metabolic |
| Regulatory status | Not FDA-approved | Investigational |
| How it's obtained | Research-only | Research-only |
| Key human source | Dalmasso, Gastroenterology 2008 | Leffler, Gastroenterology 2015 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
KPV is preclinical, with a specific PepT1 and NF-kB mechanism and reproducible mouse colitis data, and essentially no human trials. Larazotide is the more advanced molecule and the more instructive failure: its Phase 2b CeliAction trial found the 0.5 mg dose reduced symptoms versus placebo, but the pivotal Phase 3 CeDLara trial was stopped in 2022 after an interim analysis showed it would not meet its primary symptom endpoint. Larazotide is investigational and not FDA-approved for anything, and what evidence it has lives inside diagnosed celiac disease, not general 'leaky gut'. Neither is a demonstrated treatment for intestinal permeability; one has no human data, and the other has human data that came out negative.
KPV fits if
KPV suits the reader who wants to follow an early anti-inflammatory gut mechanism and accepts that the evidence stops at mice.
Larazotide fits if
Larazotide is the more relevant read for anyone specifically interested in celiac disease and tight-junction biology, and for seeing why a failed Phase 3 outweighs a supplement label.
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm KPV availability before ordering.
